stop_circleTerminated/Withdrawn

Headache

Efficacy of a Single Dose of Aspirin vs. acetaminophen in Tension Type Headache

Trial purpose

The purpose of this trial is to determine if a single, oral dose of a fast release aspirin 1000 mg provides relief compared to acetaminophen 1000 mg and placebo in subjects with tension-type headache pain.

Key Participants Requirements

Sex

Both

Age

18 - 65 Years

Trial summary

Enrollment Goal
9
Trial Dates
March 2012 - June 2012
Phase
Phase 3
Could I Receive a placebo
Yes
Products
Bayer Advanced Aspirin (Acetylsalicylic acid, BAY1019036)
Accepts Healthy Volunteer
Yes

Where to participate

StatusInstitutionLocation
Terminated
Westside Family Medical CenterKalamazoo, 49009, United States

Primary Outcome

  • Time to meaningful pain relief (defined as the time when the subject indicates pain relief that is meaningful to the subject)
    date_rangeTime Frame:
    Up to 2 hours post-dose
    enhanced_encryption
    Safety Issue:
    No

Secondary Outcome

  • Time to first perceptible relief
    Is defined as the time when the subject presses the first stopwatch
    date_rangeTime Frame:
    Up to 2 hours post-dose
    enhanced_encryption
    Safety Issue:
    No
  • Time to first perceptible relief confirmed
    The subjects would meet this outcome if they answer “yes” when asked directly after stopping the first stopwatch, if they marked a “1” on the relief pain scale or if they stopped the 2nd stop watch.
    date_rangeTime Frame:
    Up to 2 hours post-dose
    enhanced_encryption
    Safety Issue:
    No
  • Change from baseline in pain intensity score at different time points (on an 11-point Categorical Pain Intensity Scale, 0 = no pain, 10 = severe pain)
    date_rangeTime Frame:
    At baseline, 30, 60, 90 and 120 minutes post-dose, and immediately prior to the use of any rescue medication
    enhanced_encryption
    Safety Issue:
    No
  • Pain Relief on 5-point Categorical Scale (0 = no relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief, and 4 = complete relief)
    date_rangeTime Frame:
    At 30, 60, 90 and 120 minutes post-dose, and immediately prior to the use of any rescue medication
    enhanced_encryption
    Safety Issue:
    No
  • Summed time weighted of Pain Intensity Differences (PID) scores over first hour (SPID0-1)
    date_rangeTime Frame:
    Up to 1 hour
    enhanced_encryption
    Safety Issue:
    No
  • Summed time weighted of Pain Intensity Differences (PID) scores over 2 hours (SPID0-2)
    date_rangeTime Frame:
    Up to 2 hours
    enhanced_encryption
    Safety Issue:
    No
  • Summed time weighted total pain relief scores over first hour (TOTPAR0-1)
    date_rangeTime Frame:
    Up to 1 hour
    enhanced_encryption
    Safety Issue:
    No
  • Summed time weighted of Total Pain Relief Scores (TOTPAR) scores over 2 hours (TOTPAR0-2)
    date_rangeTime Frame:
    Up to 2 hours
    enhanced_encryption
    Safety Issue:
    No
  • Summed, time weighted of Pain Relief and Pain Intensity Differences (PID) over first hour (SPRID0-1)
    date_rangeTime Frame:
    Up to 1 hour
    enhanced_encryption
    Safety Issue:
    No
  • Summed, time weighted of Pain Relief and Pain Intensity Differences (PID) over 2 hours (SPRID0-2)
    date_rangeTime Frame:
    Up to 2 hours
    enhanced_encryption
    Safety Issue:
    No
  • Time to first intake of rescue medication
    date_rangeTime Frame:
    Up to 2 hours
    enhanced_encryption
    Safety Issue:
    No
  • Cumulative proportion of subjects taking rescue medication by time point
    date_rangeTime Frame:
    Up to 2 hours
    enhanced_encryption
    Safety Issue:
    No
  • Global assessment of the investigational product as a pain reliever: 0 = poor, 1 = fair, 2 = good, 3 = very good or 4 = excellent
    date_rangeTime Frame:
    At 2 hours post-dose or immediately before the first intake of rescue medication, whichever is earlier
    enhanced_encryption
    Safety Issue:
    No
  • Safety variable will be summarized using descriptive statistic based on adverse events collection
    date_rangeTime Frame:
    Up to 5 days post-dose
    enhanced_encryption
    Safety Issue:
    Yes

Trial design

A Double-Blind, Randomized, Parallel, Placebo-Controlled Trial Assessing the Analgesic Efficacy of a Single Dose of Fast Release Aspirin 1000 mg and Acetaminophen 1000 mg in Tension Type Headache Pain
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
Randomized
Blinding
Double Blind
Assignment
Parallel Assignment
Trial Arms
3